About Revance Therapeutics
Revance Therapeutics is a company based in Newark (United States) founded in 2002 was acquired by Crown Laboratories in February 2025. Revance Therapeutics has raised $154.56 million across 5 funding rounds from investors including Crown Laboratories, SVB Securities and Medicis Pharmaceutical. The company has 597 employees as of December 31, 2023. Revance Therapeutics has completed 1 acquisition, including HintMD. Revance Therapeutics offers products and services including DAXXIFY, Hyaluronic Acid Filler, and Microneedling Brand. Revance Therapeutics operates in a competitive market with competitors including Castle Creek Pharma, Dermavant, Sol-Gel Technologies, Bausch Health and Hugel, among others.
- Headquarter Newark, United States
- Employees 597 as on 31 Dec, 2023
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Revance Therapeutics, Inc.
-
Annual Revenue
$234.04 M (USD)77as on Dec 31, 2023
-
Net Profit
-$323.99 M (USD)9as on Dec 31, 2023
-
EBITDA
-$310.65 M (USD)1as on Dec 31, 2023
-
Total Equity Funding
$154.56 M (USD)
in 5 rounds
-
Latest Funding Round
$10 M (USD), Series E
Oct 22, 2013
-
Investors
Crown Laboratories
& 12 more
-
Employee Count
597
as on Dec 31, 2023
- Investments & Acquisitions
-
Acquired by
Crown Laboratories
(Feb 08, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Revance Therapeutics
Revance Therapeutics offers a comprehensive portfolio of products and services, including DAXXIFY, Hyaluronic Acid Filler, and Microneedling Brand.
Acetylcholine release inhibitor for treating glabellar lines in adults.
Product for aesthetic enhancements and skincare applications.
Device for skin rejuvenation and therapeutic applications.
People of Revance Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Revance Therapeutics
Revance Therapeutics has successfully raised a total of $154.56M across 5 strategic funding rounds. The most recent funding activity was a Series E round of $10 million completed in October 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Revance Therapeutics
Revance Therapeutics has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Crown Laboratories, SVB Securities and Medicis Pharmaceutical.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in life sciences firms across all stages.
|
Locked | Locked | Locked | |
|
Growth-stage healthcare companies are invested in by EW Healthcare Partners.
|
Locked | Locked | Locked | |
|
Investments are made in US life sciences and energy companies.
|
Locked | Locked | Locked |
Investor details for Revance Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Revance Therapeutics
Revance Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include HintMD.
Investment portfolio details for Revance Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Users are connected to aesthetic physicians for customized treatment plans.
|
Locked | Locked | 2014 | Locked |
Complete acquisition details for Revance Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Revance Therapeutics
Detailed financials for Revance Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Revance Therapeutics Comparisons
Peer comparison for Revance Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Revance Therapeutics
Revance Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Castle Creek Pharma, Dermavant, Sol-Gel Technologies, Bausch Health and Hugel, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory skin diseases are developed.
|
|
| Locked | Locked | Locked |
Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis.
|
|
| Locked | Locked | Locked |
Therapeutics for multiple diseases including dermatology and neurology are developed.
|
|
| Locked | Locked | Locked |
Therapeutics in aesthetics are developed, including botulinum toxin products.
|
Detailed competitors of Revance Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Revance Therapeutics
Complete news archive for Revance Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Revance Therapeutics
Revance Therapeutics was founded in 2002 and raised its 1st funding round 5 years after it was founded.
Revance Therapeutics is headquartered in Newark, United States. It is registered at Newark, New Jersey, United States.
Mark Foley is the current CEO of Revance Therapeutics.
Revance Therapeutics is a funded company, having raised a total of $154.56M across 5 funding rounds to date.
As of Dec 31, 2023, the latest employee count at Revance Therapeutics is 597.
Annual revenue of Revance Therapeutics is $234.04M as on Dec 31, 2023.
Revance Therapeutics was founded in 2002 and is headquartered in Newark, United States. Operations focus on the aesthetic medicine sector, where innovative neurotoxin products for skin treatments are developed. A proprietary platform technology is used to facilitate delivery of large macromolecules across the skin. The pipeline includes RT001 for lateral canthal lines and RT002 for glabellar lines, with applications extended to therapies for Hyperhidrosis and Cervical Dystonia.
Revance Therapeutics's top competitors include Dermavant, Bausch Health and Sol-Gel Technologies.
Revance Therapeutics offers DAXXIFY, Hyaluronic Acid Filler, and Microneedling Brand.
Revance Therapeutics has made 1 acquisition, including HintMD.
Revance Therapeutics has 13 investors. Key investors include Crown Laboratories, SVB Securities, Medicis Pharmaceutical, Delphi Ventures, and EW Healthcare Partners.